After several years of courtroom battles, the U.S. Supreme Court granted cert to decide whether a state can ban data mining (i.e., tracking the sale of prescription drug information that identifies prescribers and patients for commercial marketing purposes).
Below are the briefs for the State of Vermont (petitioner), IMS Health, Inc. (respondent), and the Pharmaceutical Research and Manufacturers of America (amicus).
Some pharma companies use data-mining to track whether their off-label marketing techniques are effective. It will be interesting to see whether the U.S. Attorney General and other state attorneys general file briefs. Stay tuned, this is a very important case for health care fraud.
Here is the State of Vermont's brief:
Here is IMS Health, Inc.'s brief:
Here is PhRMA's amicus brief: